Encoded Therapeutics
The Analytical Sciences Associate supports the NC Analytical Sciences department within the Biotechnology industry. This mid-senior level role requires a Bachelor's Degree and focuses on scientific analysis and data interpretation.
Headquarters
South San Francisco, California, United States
Company Size
51-200 employees
Founded
2014
Encoded Therapeutics is a biotechnology company focused on translating next-generation science into transformative gene therapies for neurological disorders. The company's novel targeting and regulation platform is designed to overcome first-generation gene therapy challenges by enabling greater gene specificity, cell selectivity, and potency. Encoded's lead program, ETX101, is currently in pivotal clinical development for Dravet Syndrome, with a broader precision genetic medicines neurology pipeline underway.
Encoded Therapeutics Presents Positive Interim Efficacy Data from Initial Dose Levels of Phase 1/2 Trials Evaluating ETX101 Gene Therapy in Dravet Syndrome
Dec 5, 2025
Encoded deciphers path to pivotal trial with phase 1/2 Dravet gene therapy data
Dec 5, 2025
Phase III update Stokes hope; Dravet game-change Encoded?
Jan 12, 2026
Headquarters
San Francisco, CA
Company Size
201-500 employees
Founded
2018
Industry
Technology
Glassdoor Rating
4.2 / 5
Sarah Johnson
Chief Executive Officer
Michael Chen
Chief Technology Officer
Emily Williams
VP of Engineering
David Rodriguez
VP of Product
Jessica Thompson
Chief Financial Officer
Andrew Park
VP of Sales
View leadership team, funding history,
and employee contacts for Encoded Therapeutics.
Encoded Therapeutics didn’t post a salary, so this is our estimate from similar listings.
54% below the average for this role
Encoded Therapeutics Announces U.S. FDA Breakthrough Therapy Designation Granted to ETX101 for the Treatment of Dravet Syndrome
Jan 12, 2026